View Older Stories View More Recent Stories

Dec 5, 2023 07:31AM Allarity (ALLR) Announces Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Dec 5, 2023 07:30AM Allarity’s Early Phase 2 Stenoparib Data Indicates Clinical Benefit in Women with Advanced Ovarian Cancer Selected with DRP® Companion Diagnostic
Oct 2, 2023 07:00AM Allarity Therapeutics to Present at Biomarkers Europe 2023
Aug 30, 2023 04:07PM Allarity Therapeutics (ALLR) Reports Publication on DRP Companion Diagnostic for Dovitinib
Aug 30, 2023 04:05PM PLOS ONE Publishes Data on Allarity Therapeutics’ DRP® Companion Diagnostic for Dovitinib
Jul 31, 2023 06:03AM Allarity Therapeutics (ALLR) and FivepHusion Partner to Support Clinical Development of Deflexifol with DRP
Jul 31, 2023 06:00AM Allarity Therapeutics and FivepHusion Announce Collaboration to Support Clinical Development of Deflexifol™ with DRP® Companion Diagnostics
Jul 24, 2023 06:00AM Allarity Therapeutics Strengthens Board of Directors with Appointment of Three Accomplished Biotechnology Executives
Jul 6, 2023 06:00AM Allarity Therapeutics (ALLR) Prices 2.44M Share Offering at $4.50/sh
Jul 6, 2023 06:00AM Allarity Therapeutics, Inc. Announces Pricing of $11 Million Public Offering
Jul 5, 2023 09:46AM Allarity Therapeutics (ALLR) Reports Initial Data from Phase 2 Trial of IXEMPRA Indicate Potential for Improved Clinical Benefit in DRP-Selected Metastatic Breast Cancer Patients
Jul 5, 2023 09:45AM Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Jun 28, 2023 11:55AM Allarity Therapeutics Announces Reverse Stock Split of Common Stock
Jun 28, 2023 05:24AM Allarity Therapeutics (ALLR) Provides Update on Previously Announced Reverse Stock Split
Jun 27, 2023 06:16PM Allarity Therapeutics Announces Clarification of Effective Date for Reverse Stock Split
Jun 20, 2023 04:05PM Allarity Therapeutics Announces Adjournment of Special Meeting of Stockholders
May 30, 2023 06:00AM First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
May 30, 2023 06:00AM First Prospective Clinical Validation of Allarity's DRP® Companion Diagnostic to be Presented at 2023 ASCO Annual Meeting
Apr 19, 2023 09:18AM Allarity Therapeutics (ALLR) Prices $7.5 Million Public Offering of Common Stock, Warrants
Apr 19, 2023 09:17AM Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
Apr 19, 2023 09:17AM Allarity Therapeutics, Inc. Announces Pricing of $7.5 Million Public Offering
Apr 11, 2023 07:00AM Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
Apr 11, 2023 07:00AM Abstract Evaluating Allarity’s DRP® Companion Diagnostic for Cisplatin Accepted at 2023 ASCO Annual Meeting
Mar 28, 2023 06:01AM Allarity Therapeutics (ALLR) Provides Updates for IXEMPRA and Stenoparib Phase 2 Studies
Mar 28, 2023 06:00AM Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
Mar 28, 2023 06:00AM Allarity Therapeutics Provides Updates for IXEMPRA and Stenoparib Phase 2 Monotherapy Clinical Studies
Mar 24, 2023 06:00AM Allarity Therapeutics (ALLR) Announces 1:35 Reverse Stock Split
Mar 24, 2023 06:00AM Allarity Therapeutics Announces Reverse Stock Split of Common Stock
Mar 24, 2023 06:00AM Allarity Therapeutics Announces Reverse Stock Split of Common Stock
Mar 20, 2023 06:01AM Allarity Therapeutics (ALLR) Doses First Patient in Phase 1b Trial of Dovitinib and Stenoparib Combination
Mar 20, 2023 06:00AM Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
Mar 20, 2023 06:00AM Allarity Therapeutics Doses First Patient in Phase 1b Clinical Trial Evaluating Dovitinib and Stenoparib Combination in Advanced Solid Tumors
Jan 20, 2023 04:01PM Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Jan 20, 2023 04:01PM Allarity Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders
Dec 1, 2022 04:25PM Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
Dec 1, 2022 04:25PM Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
Nov 15, 2022 04:03PM Allarity Therapeutics (ALLR) Reports Q3 Net Loss of $5M, Cash Position of $3.9M
Nov 15, 2022 04:01PM Allarity Therapeutics Reports Third Quarter 2022 Financial Results
Nov 15, 2022 04:01PM Allarity Therapeutics Reports Third Quarter 2022 Financial Results
Nov 7, 2022 06:15PM Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
Nov 7, 2022 06:15PM Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
Oct 11, 2022 04:05PM Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
Oct 11, 2022 04:05PM Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
Sep 26, 2022 06:01AM Allarity Therapeutics (ALLR) Appoints Jerry McLaughlin to its Board
Sep 26, 2022 06:00AM Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
Sep 26, 2022 06:00AM Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
Sep 16, 2022 06:00AM Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
Sep 16, 2022 06:00AM Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
Sep 12, 2022 04:10PM Allarity Therapeutics Announces Appointment of New Auditor
Sep 12, 2022 04:10PM Allarity Therapeutics Announces Appointment of New Auditor
View More Recent Stories View Older Stories